Castle Biosciences Management
Management criteria checks 2/4
Castle Biosciences' CEO is Derek Maetzold, appointed in Sep 2007, has a tenure of 17.75 years. total yearly compensation is $6.94M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 1.22% of the company’s shares, worth $5.65M. The average tenure of the management team and the board of directors is 4.8 years and 4.6 years respectively.
Key information
Derek Maetzold
Chief executive officer
US$6.9m
Total compensation
| CEO salary percentage | 10.31% |
| CEO tenure | 17.8yrs |
| CEO ownership | 1.2% |
| Management average tenure | 4.8yrs |
| Board average tenure | 4.6yrs |
Recent management updates
Recent updates
Some Confidence Is Lacking In Castle Biosciences, Inc. (NASDAQ:CSTL) As Shares Slide 28%
May 23
When Should You Buy Castle Biosciences, Inc. (NASDAQ:CSTL)?
Apr 16Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern
Apr 14Pinning Down Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is Difficult Right Now
Feb 25
Positive Clinical Adoption Of DecisionDx Tests Will Strengthen Future Market Position
Strong revenue growth driven by increased adoption of DecisionDx tests and promising market expansion suggests potential for significant future earnings.Castle Biosciences (NASDAQ:CSTL) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Dec 12Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Oct 15Castle Biosciences: Inflection Into Profitability
Aug 16Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Aug 11Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 08Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Aug 04Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Jul 12Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
Apr 30Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$5m |
| Dec 31 2024 | US$7m | US$716k | US$18m |
| Sep 30 2024 | n/a | n/a | US$6m |
| Jun 30 2024 | n/a | n/a | -US$3m |
| Mar 31 2024 | n/a | n/a | -US$31m |
| Dec 31 2023 | US$2m | US$686k | -US$57m |
| Sep 30 2023 | n/a | n/a | -US$76m |
| Jun 30 2023 | n/a | n/a | -US$89m |
| Mar 31 2023 | n/a | n/a | -US$72m |
| Dec 31 2022 | US$8m | US$660k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$53m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$7m | US$625k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$23m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$5m | US$550k | -US$10m |
| Sep 30 2020 | n/a | n/a | -US$3m |
| Jun 30 2020 | n/a | n/a | US$7m |
| Mar 31 2020 | n/a | n/a | US$6m |
| Dec 31 2019 | US$4m | US$770k | US$3m |
| Sep 30 2019 | n/a | n/a | US$4m |
| Jun 30 2019 | n/a | n/a | -US$6m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$791k | US$410k | -US$10m |
Compensation vs Market: Derek's total compensation ($USD6.94M) is above average for companies of similar size in the US market ($USD2.69M).
Compensation vs Earnings: Derek's compensation has increased whilst the company is unprofitable.
CEO
Derek Maetzold (63 yo)
Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 17.8yrs | US$6.94m | 1.22% $ 5.6m | |
| CFO & Treasurer | 7.5yrs | US$2.31m | 0.15% $ 692.0k | |
| Chief Operating Officer | 4.8yrs | US$1.22m | 0.57% $ 2.6m | |
| Chief Commercial Officer | 4.8yrs | US$2.45m | 0.28% $ 1.3m | |
| Vice President of Investor Relations & Corporate Affairs | no data | no data | no data | |
| Vice President of Sales | 3yrs | no data | no data | |
| VP of Marketing & Brand Manager of Uveal Melanoma (UM) | less than a year | no data | no data | |
| Vice President of Human Resources | 4.9yrs | no data | no data | |
| Senior Vice President of Medical | 2.1yrs | no data | no data |
Experienced Management: CSTL's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 17.8yrs | US$6.94m | 1.22% $ 5.6m | |
| Independent Chairman of the Board | 12.8yrs | US$297.15k | 0.076% $ 350.8k | |
| Independent Director | 6.5yrs | US$279.65k | 0.076% $ 350.8k | |
| Independent Director | 4.1yrs | US$319.68k | 0.090% $ 413.7k | |
| Independent Director | 1.3yrs | US$550.00k | 0.049% $ 223.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.9yrs | US$267.15k | 0.078% $ 358.6k | |
| Independent Director | 5.2yrs | US$277.15k | 0.076% $ 350.8k | |
| Independent Director | 3.9yrs | US$264.65k | 0.094% $ 435.2k |
Experienced Board: CSTL's board of directors are considered experienced (4.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/01 02:07 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Castle Biosciences, Inc. is covered by 9 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |